Hengrui PD-1 is officially approved as a clinical

Original: Winter On January 9, the CDE clinical tacit permission column was updated, in which Hengrui PD-1 (carrizumab) was approved for a clinical application: in combination with albumin paclitaxel and apatinib, it was used for the local advanced or metastatic triple negative breast cancer that could not be removed surgically and had not received systematic anti-tumor treatment in the previous stage of recurrence and metastasis On May 29, 2019, carrizumab, a PD-1 inhibitor independently developed by Hengrui pharmaceutical, was officially approved by the State Drug Administration for the treatment of relapsed or refractory classic Hodgkin's lymphoma patients who had at least undergone second-line system chemotherapy Carolyn Ju monoclonal antibody was successfully approved, although it was made in third homes, but it was unable to estimate the force Currently, in addition to the approval of Hodgkin lymphoma, 3 new indications have been reported, namely, hepatocellular carcinoma, non squamous non-small cell lung cancer and squamous cell carcinoma of the diet Incidence rate is high in China In addition, insight database shows that there are 31 ongoing clinical trials (according to clinical registration number), involving esophageal cancer, liver cell cancer, non-small cell lung cancer, small cell lung cancer and other cancer types Nine of them are in phase III clinical practice and 14 are in phase II clinical practice.